Narmac ... It is frustrating, trying to regain some momentum and traction, given the issues facing RVX. I am sure thee are some new faces super attractied to the BTD, science, and publications. And plenty of others that unattracted to the management clown show, lack of meaningful progress, company finances, and ongoing uncertainty.

In an extreme pinch, I would "hope" that there would be a few BP's out there willing (and maybe even "competing") to take RVX "out" in the $3-5 per share minimum range if things become bleak and desperate for RVX, while Don and the BoD hold out for the big bucks a while longer. But BP's simply MUST be watching closely, as it could impact their sales and revenues within a few years potentially, and also just to control this technology and get deep into the epigenetics space and runway, which seems very interesting for the future.

Obviously, a good meeting with the FDA in August, hopefully with encouraging news, and getting some funding lined up in the not too distant future will go a long way toward stabilizing enthusiasm and pps again. Hopefully, those things aren't just wishful thinking. And also hoping Eversana is crafting and developing a strong, logical, and realistic strategic plan for reaching those interim targets and goals toward the long term goals, success and breakthrough milestones.

I know I said hope a few times, and "hope" is not a strategy, ... but it's all I got right now haha.